An observational study of gout prevalence and quality of care in a national australian general practice population

Journal of Rheumatology

Volumn 42, Issue 9, 2015, Pages 1702-1707

  Robinson, Philip C ^a   Taylor, William J ^b   Dalbeth, Nicola ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Gout Serum; Quality of Care; Urate Prevalence

Indexed keywords

ALLOPURINOL; URATE; ANTIGOUT AGENT; URIC ACID;

ADULT; AGE; AGED; ARTICLE; AUSTRALIA; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; FEMALE; GENERAL PRACTICE; GENERAL PRACTITIONER; GOUT; HEALTH CARE QUALITY; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; URIC ACID BLOOD LEVEL; BLOOD; ELECTRONIC HEALTH RECORD; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALLOPURINOL; AUSTRALIA; ELECTRONIC HEALTH RECORDS; FEMALE; GENERAL PRACTICE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; QUALITY OF HEALTH CARE; SEX FACTORS; URIC ACID; YOUNG ADULT;

EID: 84940688649     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.150310     Document Type: Article

References (36)

1. Dalbeth N, Collis J, Gregory K, Clark B, Robinson E, McQueen FM. Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology 2007;46:1804-7.
2. Robinson PC, Merriman TR, Herbison P, Highton J. Hospital admissions associated with gout and their co-morbidities in New Zealand and England 1999-2009. Rheumatology 2013;52:118-26.
3. Robinson PC, Horsburgh S. Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities. Maturitas 2014;78:245-51.
4. Winnard D, Wright C, Taylor WJ, Jackson G, Te Karu L, Gow PJ, et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology 2012;51:901-9.
5. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population. Arthritis Rheum 2011;63:3136-41.
6. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012;64:1431-46.
7. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence-based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
8. Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology 2009;48 Suppl 2:ii9-14.
9. Reach G. Treatment adherence in patients with gout. Joint Bone Spine 2011;78:456-9.
10. Pascual E, Sivera F. Why is gout so poorly managed? Ann Rheum Dis 2007;66:1269-70.
11. Cottrell E, Crabtree V, Edwards JJ, Roddy E. Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice. BMC Fam Pract 2013;14:170.
12. Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925-34.
13. Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008;67:960-6.
14. Robinson P, Taylor W, Merriman T. Systematic review of the prevalence of gout and hyperuricemia in Australia. Intern Med J 2012;42:997-1007.
15. Jackson G, Dalbeth N, Te Karu L, Winnard D, Gow P, Gerard C, et al. Variation in gout care in Aotearoa New Zealand: a national analysis of quality markers. N Z Med J 2014;127:37-47.
16. Winnard D, Wright C, Jackson G, Gow P, Kerr A, McLachlan A, et al. Gout, diabetes and cardiovascular disease in the Aotearoa New Zealand adult population: co-prevalence and implications for clinical practice. N Z Med J 2013;126:53-64.
17. Jackson G, Wright C, Thornley S, Taylor WJ, Te Karu L, Gow PJ, et al. Potential unmet need for gout diagnosis and treatment: capture-recapture analysis of a national administrative dataset. Rheumatology 2012;51:1820-4.
18. Hamburger M, Baraf HS, Adamson TC 3rd, Basile J, Bass L, Cole B, et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med 2011;123:3-36.
19. Roddy E. Gout: presentation and management in primary care. Arthritis Res UK 2011;6:9.
20. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007;46:1372-4.
21. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJ, Lozano R, Inoue M. Age standardization of rates: a new WHO standard. World Health Organization, 2001. [Internet. Accessed June 9, 2015.] Available from: www.who.int/healthinfo/paper31.pdf
22. Pink B. Socio-economic Indexes for Areas (SEIFA) 2011. Canberra: Australian Bureau of Statistics; 2013.
23. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.
24. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis 2015;74:661-7.
25. Wijnands JM, Viechtbauer W, Thevissen K, Arts IC, Dagnelie PC, Stehouwer CD, et al. Determinants of the prevalence of gout in the general population: a systematic review and meta-regression. Eur J Epidemiol 2015;30:19-33.
26. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006;12:61-5.
27. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006;33:1646-50.
28. Dalbeth N. Gout-hit the target. Best Pract J 2007;8:9-18.
29. Hayward RA, Rathod T, Roddy E, Muller S, Hider SL, Mallen CD. The association of gout with socioeconomic status in primary care: a cross-sectional observational study. Rheumatology 2013; 52:2004-8.
30. Kienhorst LB, Janssens HJ, Fransen J, van de Lisdonk EH, Janssen M. Arthritis of the first metatarsophalangeal joint is not always gout: a prospective cohort study in primary care patients. Joint Bone Spine 2014;81:342-6.
31. Janssens HJ, Fransen J, van de Lisdonk EH, van Riel PL, van Weel C, Janssen M. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med 2010;170:1120-6.
32. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51:321-5.
33. Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009;36:1273-82.
34. Robinson PC, Dalbeth N. Advances in pharmacotherapy for the treatment of gout. Expert Opin Pharmacother 2015;16:533-46.
35. Lindsay K, Gow P, Vanderpyl J, Logo P, Dalbeth N. The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach. J Clin Rheumatol 2011;17:1-6.
36. Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology 2007;46:1441-4.